Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurodegenerative disease that affects both upper and lower motor neurons, which results in loss of muscle control and eventual paralysis [1]. Currently, there are as yet unresolved challenges regarding e...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-03-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006420300156 |
| _version_ | 1828484751984427008 |
|---|---|
| author | G.Y. Wang S.L. Rayner R. Chung B.Y. Shi X.J. Liang |
| author_facet | G.Y. Wang S.L. Rayner R. Chung B.Y. Shi X.J. Liang |
| author_sort | G.Y. Wang |
| collection | DOAJ |
| description | Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurodegenerative disease that affects both upper and lower motor neurons, which results in loss of muscle control and eventual paralysis [1]. Currently, there are as yet unresolved challenges regarding efficient drug delivery into the central nervous system (CNS). These challenges can be attributed to multiple factors including the presence of the blood-brain barrier (BBB), blood-spinal cord barrier (BSCB), as well as the inherent characteristics of the drugs themselves (e.g. low solubility, insufficient bioavailability/bio-stability, 'off-target' effects) etc. As a result, conventional drug delivery systems may not facilitate adequate dosage of the required drugs for functional recovery in ALS patients. Nanotechnology-based strategies, however, employ engineered nanostructures that show great potential in delivering single or combined therapeutic agents to overcome the biological barriers, enhance interaction with targeted sites, improve drug bioavailability/bio-stability and achieve real-time tracking while minimizing the systemic side-effects. This review provides a concise discussion of recent advances in nanotechnology-based strategies in relation to combating specific pathophysiology relevant to ALS disease progression and investigates the future scope of using nanotechnology to develop innovative treatments for ALS patients. |
| first_indexed | 2024-12-11T09:01:12Z |
| format | Article |
| id | doaj.art-a57469f709eb42039481c8718a316df7 |
| institution | Directory Open Access Journal |
| issn | 2590-0064 |
| language | English |
| last_indexed | 2024-12-11T09:01:12Z |
| publishDate | 2020-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj.art-a57469f709eb42039481c8718a316df72022-12-22T01:13:46ZengElsevierMaterials Today Bio2590-00642020-03-016100055Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosisG.Y. Wang0S.L. Rayner1R. Chung2B.Y. Shi3X.J. Liang4Huaihe Hospital, Henan University, Kaifeng, Henan, 475004, China; Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW 2109, AustraliaCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW 2109, AustraliaCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW 2109, AustraliaCentre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW 2109, Australia; Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan, 475004, China; Corresponding author. Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing, 100190, China; Corresponding author.Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurodegenerative disease that affects both upper and lower motor neurons, which results in loss of muscle control and eventual paralysis [1]. Currently, there are as yet unresolved challenges regarding efficient drug delivery into the central nervous system (CNS). These challenges can be attributed to multiple factors including the presence of the blood-brain barrier (BBB), blood-spinal cord barrier (BSCB), as well as the inherent characteristics of the drugs themselves (e.g. low solubility, insufficient bioavailability/bio-stability, 'off-target' effects) etc. As a result, conventional drug delivery systems may not facilitate adequate dosage of the required drugs for functional recovery in ALS patients. Nanotechnology-based strategies, however, employ engineered nanostructures that show great potential in delivering single or combined therapeutic agents to overcome the biological barriers, enhance interaction with targeted sites, improve drug bioavailability/bio-stability and achieve real-time tracking while minimizing the systemic side-effects. This review provides a concise discussion of recent advances in nanotechnology-based strategies in relation to combating specific pathophysiology relevant to ALS disease progression and investigates the future scope of using nanotechnology to develop innovative treatments for ALS patients.http://www.sciencedirect.com/science/article/pii/S2590006420300156NanotechnologyAmyotrophic lateral sclerosis (ALS)Blood-brain barrierNeurodegenerative diseasesCentral nervous system (CNS) |
| spellingShingle | G.Y. Wang S.L. Rayner R. Chung B.Y. Shi X.J. Liang Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis Materials Today Bio Nanotechnology Amyotrophic lateral sclerosis (ALS) Blood-brain barrier Neurodegenerative diseases Central nervous system (CNS) |
| title | Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis |
| title_full | Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis |
| title_fullStr | Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis |
| title_full_unstemmed | Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis |
| title_short | Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis |
| title_sort | advances in nanotechnology based strategies for the treatments of amyotrophic lateral sclerosis |
| topic | Nanotechnology Amyotrophic lateral sclerosis (ALS) Blood-brain barrier Neurodegenerative diseases Central nervous system (CNS) |
| url | http://www.sciencedirect.com/science/article/pii/S2590006420300156 |
| work_keys_str_mv | AT gywang advancesinnanotechnologybasedstrategiesforthetreatmentsofamyotrophiclateralsclerosis AT slrayner advancesinnanotechnologybasedstrategiesforthetreatmentsofamyotrophiclateralsclerosis AT rchung advancesinnanotechnologybasedstrategiesforthetreatmentsofamyotrophiclateralsclerosis AT byshi advancesinnanotechnologybasedstrategiesforthetreatmentsofamyotrophiclateralsclerosis AT xjliang advancesinnanotechnologybasedstrategiesforthetreatmentsofamyotrophiclateralsclerosis |